Intelligence Β· Clinical Pipeline
Phase I Pipeline Programs
First-in-human and early clinical safety studies in Phase I.
- Programs
- 4,713
Quick answer
NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.
Top sponsors
- BRIGHT MINDS BIOSCIENCES 327 programs
- Takeda 276 programs
- Anaxis Pharma 204 programs
- Chinese Academy of 190 programs
- United Therapeutics Europe 184 programs
- Teva Pharma 154 programs
- First People's Hospital 149 programs
- Regeneron UK 126 programs
- Boehringer Ingelheim 94 programs
- Sunshine Guojian Pharmaceutical 85 programs
- Lakefront Biotherapeutics NV 62 programs
- HOFFMANN-LA ROCHE 58 programs
-
ziftomenib
Kura Oncology
Gastrointestinal Stromal Tumor (GIST)
1 trial -
zimberelimab
Arcus Biosciences
Advanced Solid Tumors
1 trial -
ziv-aflibercept
Regeneron UK Limited
Lymphoma
2 trials -
ziv-aflibercept
Regeneron UK Limited
Cancer
2 trials -
Ξ±-lactalbumin vaccine
Anixa Biosciences Inc
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer
1 trial -
Ξ³Ξ΄T Cell infusion agent
The First People's Hospital of Lianyungang
Leukemia, B-cell
1 trial -
ββA Phase 1, Open-Label, Multiple-Part Trial to Evaluate the Drug-Drug Interaction Potential of PRAX-628 in Healthy Participantsβ
Chongqing Precision Biotech Co., Ltd
Epilepsy
1 trial -
ββAMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors β
Amgen
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors
1 trial -
βINSIGHTβ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors
The George Institute
Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)
1 trial
Frequently asked questions
How many Phase I pipeline programs are in the directory?
4,713 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.
Data attribution: Data sources Β· All pipeline programs